RxDoctor Payments Data

Biren Shah, MD

Family Medicine · Brea, CANPI 1710086533

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 77 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$239
  • Pfizer$201
  • GSK$184
  • Lilly USA, LLC$160
  • Merck$117
  • Amgen$105
  • plus $389 from 13 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,35697%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,396 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$139,128
Medicare patients
295
Services billed
1,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate145$190,287
EliquisApixaban177$176,845
OzempicSemaglutide68$73,230
MounjaroTirzepatide49$68,075
JardianceEmpagliflozin30$38,702
JanumetSitagliptin Phos/Metformin Hcl30$37,678
TrulicityDulaglutide20$28,622
XareltoRivaroxaban18$18,845
TradjentaLinagliptin23$15,279
Atorvastatin Calcium786$8,384
Wixela InhubFluticasone Propion/Salmeterol33$8,179
Losartan Potassium550$6,698
Levothyroxine Sodium415$6,050
Pantoprazole Sodium404$5,422
Testosterone46$5,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$117$227,965175 claims
PfizerEliquis$201$176,845177 claims
Lilly USA, LLCMounjaro, Trulicity$160$96,69769 claims
Novo NordiskOzempic$239$73,23068 claims
Boehringer IngelheimJardiance, Tradjenta$18$53,98153 claims
Johnson & JohnsonXarelto$45$18,84518 claims
AbbVieSynthroid$12$4,57855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Brea

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →